In cancer patients with metabolic disorders, HMGCL regulates H3K9 acetylation through β-OHB and modulates the expression of dipeptidyl peptidase-4 (DPP4) in a dose-dependent manner, leading to ferroptosis in liver cancer cells [223]. Here, DPP4 is linked to Other metabolic disease.